Most Recent
Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.
A judge has reprimanded CIMIC Group's preparations to defend a class action against it, saying a late attempt to file critical evidence was a sign something "pretty horrible" had gone on behind the scenes.
Liberal Democrat Senator David Leyonhjelm has lost his challenge to a ruling that denied his request for speedy dismissal of a defamation lawsuit by Greens Senator Sarah Hanson-Young on the grounds of Parliamentary privilege.
Pharmaceutical giant Allergan has streamlined its trade mark case against Self Care Corporation, which makes products marketed as Botox alternatives.
The Australian Securities and Investments Commission has appealed a ruling that two Westpac units did not provide personal financial advice as part of a campaign encouraging customers to roll over external superannuation accounts.
Construction giant Bechtel has reached a settlement in a lawsuit by a male worker who claims the company shrugged off his complaints of same-sex harassment as "horseplay".
A judge has found franchisor Retail Food Group made false and misleading statements to a couple whose Michel's Patisserie franchise ultimately lost over $142,000 due to allegedly poor quality products and irregular order schedules.
Canadian generic manufacturer Apotex has agreed to drop its lawsuit against India's Cipla seeking to invalidate its Australian patent for popular nasal spray Dymista.
Law firm Slater and Gordon is investigating a class action against hospitals for encouraging "excessive and unsafe" work hours by doctors, some of whom the firm found routinely work up to 100 hours per week.
The Australian Competition and Consumer Commission has dropped its claims of collusion against rail freight companies Pacific National and Aurizon, as the trial in its competition case wraps up this week.